Trial
NCT04115748
Study to Evaluate the Efficacy and Safety of Filgotinib in Participants With Active Psoriatic Arthritis Who Are Naive to Biologic DMARD Therapy
Phase IIITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Gilead Sciences
Collaborators
Lakefront Biotherapeutics NV
Condition
Psoriatic Arthritis
Intervention
Filgotinib
Why stopped
Development program terminated
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2022-05-16